Product Information
AMLODIPINE-ATORVAST 10-20 MG is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.7970 per EA under NDC 00378451893. Its NADAC has been published 652 times since Apr 9, 2014.
FDA first approved this application on Nov 29, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10; 20 mg/1; mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378451893
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM TRIHYDRATEApproval Type
Generic (ANDA)
FDA Application
ANDA200465FDA Approved
11/29/2013
TE Code
AB
On Market Since
2/11/2014
Pharmacological Classes
Price Statistics
The NADAC for AMLODIPINE-ATORVAST 10-20 MG has been published 652 times since Apr 9, 2014, and over the history we have for it it has declined 88.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7970 per EA |
|---|---|
| All-time high | $6.9238 (Jul 16, 2014) |
| All-time low | $0.6922 (Jun 19, 2024) |
| 52-week high | $1.3995 |
| 52-week low | $0.7970 |
| Median price | $2.7021 |
| Average price | $3.0965 |
| Largest weekly change | +120.1% (Dec 21, 2022) |
| Weeks tracked | 652 |
| Tracking since | Apr 9, 2014 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Amlodipine and atorvastatin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Amlodipine and atorvastatin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcium Channel Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AMLODIPINE-ATORVAST 10-20 MG?
The current National Average Drug Acquisition Cost (NADAC) for AMLODIPINE-ATORVAST 10-20 MG, manufactured by Mylan Pharmaceuticals Inc., is $0.7970 per EA (NDC 00378451893), effective Sep 30, 2026.
How has the price of AMLODIPINE-ATORVAST 10-20 MG changed over time?
Over the history we have for it, the NADAC for AMLODIPINE-ATORVAST 10-20 MG has declined 88.1%. It has been tracked across 652 weekly CMS publications since Apr 9, 2014.
What are the highest and lowest recorded NADAC prices for AMLODIPINE-ATORVAST 10-20 MG?
Since Apr 9, 2014, the NADAC for AMLODIPINE-ATORVAST 10-20 MG has ranged from a low of $0.6922 (Jun 19, 2024) to a high of $6.9238 (Jul 16, 2014), with a median of $2.7021 per EA.
Are there cheaper alternatives to AMLODIPINE-ATORVAST 10-20 MG?
No other NADAC-published product currently shares the active ingredient and strength of AMLODIPINE-ATORVAST 10-20 MG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures AMLODIPINE-ATORVAST 10-20 MG?
AMLODIPINE-ATORVAST 10-20 MG (NDC 00378451893) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.